← Leaderboards
Agustin A Garcia
University Of Southern California
$36,457
Attributed
$36,457
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $6K · FY2005–08$10K$7.5K$5K$2.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$36,457 · 3
By mechanism
M01$36,457 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Heinz Josef Lenz$20,123,312
- Don J Diamond$24,317,616
- Jeffrey Y Wong$938,530
- Jeffrey S Weber$20,866,039
- Robert C Seeger$12,536,093
Others in their field
Top investigators on “Irinotecan”
- Karen S Aboody · Layton Bioscience, Inc.$6,180,790
- Matthew Redinbo · Univ Of North Carolina Chapel Hill$6,135,457
- Mark J Ratain · University Of Chicago$6,096,817
- Chun-Su Yuan · University Of Chicago$5,916,712
- Lily Yang · Emory University$4,349,187
- Huang Chiao Huang · University Of Maryland Baltimore$3,839,651
Research focus
IrinotecanHuman SubjectDrug Screening /EvaluationClinical ResearchClinical Trial Phase IDoseDose-LimitingDrug Administration Rate /DurationDrug InteractionsDrug KineticsFundingGrantHuman Therapy EvaluationInstitutionIntraperitonealWeekAntineoplasticsClinical Trials, Phase IComputer Retrieval Of Information On Scientific Projects DatabaseDosageToxic EffectUnited States National Institutes Of HealthAnalogMaximum Tolerated Dose
Grant awards (7)
PHASE I CLINICAL AND PHARMACOKINETIC TRIAL OF INTRAPERITONEAL IRINOTECAN$6,010
M01 · FY2008 · RR · contact PI
PHASE I CLINICAL AND PHARMACOKINETIC TRIAL OF INTRAPERITONEAL IRINOTECAN$4,847
M01 · FY2007 · RR · contact PI
PHASE I CLINICAL AND PHARMACOKINETIC TRIAL OF INTRAPERITONEAL IRINOTECAN$4,354
M01 · FY2006 · RR · contact PI
PHASE I CLINICAL AND PHARMACOKINETIC TRIAL OF INTRAPERITONEAL IRINOTECAN$4,131
M01 · FY2005 · RR
Phase I Clinical and Pharmacokinetic Trial of Irinotecan$17,115
M01 · FY2004 · RR
PHASE I TRIAL OF DOCETAXEL AND IRINITECAN WEEKLY$0
M01 · FY2000 · RR
PHASE I TRIAL OF DOCETAXEL AND IRINITECAN WEEKLY$0
M01 · FY2000 · RR